Updated:
MedFocus Funds
Michael Henson's MedFocus Funds incubates early-stage medical device companies from Irvine, with 35 startups and 21 acquisitions since 2000.
MedFocus Funds
MedFocus Funds was founded in 2000 by Michael Henson, an operator who has guided more than twenty emerging medical-technology firms and chaired IPOs for six of them. The firm operates from Irvine, California, and describes its model as an incubator that creates companies around early-stage device innovation before seeking corporate acquirers or public listings. Twelve of the firms Henson founded have been bought by large multinationals. MedFocus concentrates exclusively on medical devices, backing ideas sourced through a network of physicians and industry engineers that the firm then incubates — providing capital, management, and back-office infrastructure until the companies reach commercial maturity. Its historical coverage spans cardiovascular, neurovascular, and orthopedic therapies. Among known exits, a Henson co-founded entity, Rebound Therapeutics (parent of Viseon Inc.), was acquired by Integra LifeSciences in September 2019 at a stated 4x return to shareholders. Another portfolio company, ApiFix Inc., was sold to Orthopediatrics in 2020 under the leadership of MedFocus principal Ed Roschak. The firm reports having deployed capital into 35 companies and completed 21 acquisitions since inception. Ed Roschak, a named inventor on more than 40 granted patents, joined the team after engineering and leadership roles at Hewlett-Packard and Boston Scientific-linked ventures. Co-founder Tracy Person and operations lead Maria Nevarez anchor the firm’s corporate functions, with Person overseeing more than 55 corporate transactions and the organization of 21 corporations. The most recent disclosed exit was the 2020 ApiFix acquisition negotiated by Roschak while serving as the company’s chairman. MedFocus operates an in-house incubation structure that goes beyond standard venture capital: the management company serves as corporate officer for multiple incubated entities, handling governance, risk management, and fundraising centrally. This architecture blurs the line between a fund and an operating platform, making the firm a hybrid device foundry that manufactures startups from proprietary IP and clinical relationships.
General information
Firm type
Private Equity
Year founded
2000
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Irvine
Corporate office
30 Fairbanks Ste. 100, Irvine, California 92618, United States
Principals
Michael Henson
Founder
Ed Roschak
Principal
Tracy Person
Co-Founder, Member
Maria Nevarez
Operations Manager, Member
Sector focus
Frequently asked questions
Who runs investment decisions at MedFocus Funds?
Founder Michael Henson drives sourcing and investment committee decisions, supported by principal Ed Roschak. Henson draws on experience founding more than twenty medical-technology firms and chairing six IPOs. Roschak, a named inventor on over 40 patents, contributes technical due diligence and operational leadership.
How does MedFocus source proprietary deal flow?
MedFocus builds companies from physician-and-engineer networks that surface unmet clinical needs in cardiovascular, neurovascular, and orthopedic disease. The firm does not run a traditional scout program — it relies on Henson's three-decade Rolodex and Roschak's relationships from senior roles at Hewlett-Packard, Origin Medsystems, and Boston Scientific-acquired ventures.
Is MedFocus structured as a family office or a venture firm?
MedFocus is an asset manager operating as a hybrid incubator and private equity firm — it founds companies, provides shared back-office infrastructure, and places its own team members as corporate officers. It is not a single-family office but a specialized fund platform for early-stage medical device investing.
What investment stages does MedFocus typically target?
MedFocus targets the earliest stage of device innovation — often pre-revenue, concept-stage companies it incubates internally. The firm builds management, handles regulatory groundwork, and seeks a trade sale or IPO path rather than participating in growth-stage or buyout rounds.
Does MedFocus participate in fund commitments or only direct deals?
Based on available disclosures, MedFocus appears to deploy capital exclusively through direct company creation and incubation. There is no public record of the firm making fund commitments to outside general partners.
What is MedFocus's known posture on co-investments alongside external GPs?
The public record does not detail a co-investment program. MedFocus's historical deals — including the Integra LifeSciences acquisition of Rebound Therapeutics and Orthopediatrics' purchase of ApiFix — were full acquisitions of incubated companies rather than syndicated venture rounds.
What is the MedFocus management company's relationship to its portfolio?
The management company serves as corporate officer for several portfolio firms, handling governance, risk management, contract management, and human resources. This centralization allows the incubator to reduce administrative burn for scientific founders while retaining operational control.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: